Contradicting results emerged from a retrospective study comparing the clinical characteristics and the results of targeted exome sequencing, transcriptome sequencing, and immunohistochemistry analyses in human patients with histologically confirmed angiosarcoma treated with immune checkpoint blockade-base therapy, where it was demonstrated that neither PD-L1 expression nor presence of TILs at baseline appears necessary for a response to immune checkpoint blockade (ICB) therapy [86]. Here, CD274 is linked to angiosarcoma.